NCT06119685 2025-06-03IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersIndapta Therapeutics, INC.Phase 1/2 Recruiting128 enrolled
NCT03997968 2024-12-24A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid TumorsCyteir Therapeutics, Inc.Phase 1/2 Completed169 enrolled
NCT03530683 2024-09-03A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple MyelomaPfizerPhase 1 Terminated189 enrolled
NCT04136756 2023-06-15NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaNektar TherapeuticsPhase 1 Completed30 enrolled
NCT04045028 2023-04-07A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaGenentech, Inc.Phase 1 Terminated41 enrolled
NCT02265731 2021-08-02Study Evaluating Venetoclax in Subjects With Hematological MalignanciesAbbViePhase 1/2 Completed38 enrolled